Analysis of Analgesic Trials

  • Ene I. Ette
  • Peter Lockwood
  • Raymond Miller
  • Jaap Mandema


Analgesic clinical trials are usually complex. Because of the complexity of these trials knowledge of pharmacokinetic/pharmacodynamic relationships of analgesics is limited. The consequence of this is that some recommended analgesic doses may not be optimal. The design of an analgesic clinical trial is usually of the following pattern; patients receive a single dose of an analgesic or a placebo after a pain-initiating event such as surgery, and pain intensity or pain relief is measured to assess drug efficacy at specific times after drug administration. On ethical grounds, the patients can demand a rescue medication of a known effective analgesic at any time if their pain relief is inadequate. Pain relief and remedication time—two clinical efficacy endpoints—are compared between placebo and the administered active doses of the analgesic tested.


Pain Relief Modify Release Nonlinear Mixed Effect Population Pharmacokinetic Parameter Adequate Pain Relief 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bates, D.M. and Watts, D.G. (1988). Nonlinear Regression Analysis and lis Application. Wiley, New York.CrossRefGoogle Scholar
  2. Beal, S.L. and Sheiner, L.B. (1982). Estimating population pharmacokinetics. CRC Critical Review in Biomedical Engineering 8, 195–222.Google Scholar
  3. Beal, S.L. and Sheiner, L.B. (1992). NONMEM Users Guides, Parts I-VII. University of California, San Francisco, CA.Google Scholar
  4. Dayneka, N.I., Garg, V., and Jusko, W.J. (1993). Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceuticals 21, 457–478.CrossRefGoogle Scholar
  5. Ette, E.I. and Ludden, T.M. (1995). Population pharmacokinetic modeling: The importance of informative graphics. Pharmaceutical Research 12, 1845–1855.CrossRefGoogle Scholar
  6. Laska, E.M. Siegel, C., and Sunshine, A. (1991). Onset and duration: Meas- urement and analysis. Clinical Pharmacology and Therapeutics 49, 1–5.Google Scholar
  7. Liu, C.Y. and Sambol, N.C. (1995). Pharmacodynamic analysis of analgesic trials using empirical methods. Pharmaceutical Research 12, 438–445.CrossRefGoogle Scholar
  8. Mandema, J.W. (1997). Population pharmacokinetics/pharmacodynamics of analgesics: theory and applications. In: Aarons, L., Balant, L.P., Danhof, M., et al., eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Commission of the European Communities. European Cooperation in the Field of Scientific and Technical Research, Brussels, pp. 74–82.Google Scholar
  9. Mandema, J.W. and Stanski, D.R. (1996). Population pharmacodynamic model for ketorolac analgesia. Clinical Pharmacology and Therapeutics 60, 619635.Google Scholar
  10. Mandema, J.W., Verotta, D., and Sheiner, L.B. (1992). Building population pharmacodynamic models. I. Models for covariates. Journal of Pharmacokinetics and Biopharmaceuticals 20, 58–528.Google Scholar
  11. Max, M.B., Portenoy, R.K., and Laska, E.M., eds. (1991). Advances in pain research and therapy. Volume 18: The Design of Analgesic Clinical Trials. Raven Press, New York.Google Scholar
  12. McCullagh, P. and Neider, J.A. (1989). Generalized Linear Models. Second edition. Chapman & Hall, New York.zbMATHGoogle Scholar
  13. Racine-Poon, A. and Wakefield, J. (1998). Statistical methods in population pharmacokinetic modeling. Statistical Methods in Medical Research 7, 63–84.CrossRefGoogle Scholar
  14. Sheiner, L.B. (1994). A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clinical Pharmacology and Therapeutics 56, 3098–322.Google Scholar
  15. Sheiner, L.B., Stanski, D.R., Vozeh, D.R., and Miller, R.D. (1979). Simultaneous modeling of pharmacokinetics modeling of pharmacokinetic and pharmacodynamics: Application to D-tubocurarine. Clinical Pharmacology and Therapeutics 25, 358–371.Google Scholar
  16. Velagapudi, R., Harter, J.G., Brueckner, R., and Peck, C.C. (1991). Pharmacokinetic/pharmacodynamic models in analgesic study design. In: Max, M.B., Portenoy, R.K., Laska, E.M., eds. Advances in Pain Research and Therapy, Vol. 18. Raven Press, New York, pp. 559–562.Google Scholar
  17. Wajdula, J.S., Vavra, I., Sullivan, D., Ermer, J., and Osman, M. (1994). Bromfenac. In: Lewis, A.J., Furst, D.E., eds. Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses. Second edition. Marcel Dekker, New York, pp. 267–284.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Ene I. Ette
    • 1
  • Peter Lockwood
    • 2
  • Raymond Miller
    • 2
  • Jaap Mandema
    • 3
  1. 1.Vertex Pharmaceuticals, Inc.CambridgeUSA
  2. 2.Pfizer Global Research and DevelopmentAnn ArborUSA
  3. 3.Pharsight CorporationMountain ViewUSA

Personalised recommendations